Literature DB >> 3964819

The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization.

J Tschopp, E R Podack, H J Müller-Eberhard.   

Abstract

Polymerization of C9 occurs spontaneously or can be induced by the tetramolecular complex C5b-8. Spontaneous C9 (0.15 mg/ml) polymerization required more than 3 days at 37 degrees C. In the presence of C5b-8, C9 polymerization was complete within 10 min. The molar C9:C5b-8 ratio determined the extent of tubular poly C9 formation by C5b-8-bearing phospholipid vesicles. When this ratio was 9:1 or 12:1, 72% of complex-bound C9 was present as SDS resistant tubular poly C9 (Mr = 1.1 X 10(6]. At lower C9:C5b-8 ratios, poly C9 was bound primarily in nontubular form. Tubular poly C9, as part of C5b-9, could also be generated on rabbit erythrocytes by using whole human serum as a complement source. At limiting serum concentration (molar C9 to C8 ratio approximately 2), no SDS-resistant tubular poly C9 was detected. At high serum concentration or when using serum that was supplemented with C9, up to 40% of the C9 was SDS-resistant tubular poly C9, and the rest was poly C9, which was incompletely polymerized. It is suggested that the C5b-8 complex acts as an accelerator of C9 polymerization, and that its relative concentration to C9 determines the ultrastructure of the C5b-9 complex.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3964819

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Structure of complement C6 suggests a mechanism for initiation and unidirectional, sequential assembly of membrane attack complex (MAC).

Authors:  Alexander E Aleshin; Ingrid U Schraufstatter; Boguslaw Stec; Laurie A Bankston; Robert C Liddington; Richard G DiScipio
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 2.  The role of complement system in adipose tissue-related inflammation.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Dallas Boodhoo; Stefan Vesa; Petru A Mircea; Horea Rus
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

3.  Topology of the membrane-bound form of complement protein C9 probed by glycosylation mapping, anti-peptide antibody binding, and disulfide modification.

Authors:  Véronique Rossi; Yunxia Wang; Alfred F Esser
Journal:  Mol Immunol       Date:  2010-02-12       Impact factor: 4.407

4.  The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits.

Authors:  A Abraha; B P Morgan; J P Luzio
Journal:  Biochem J       Date:  1988-04-01       Impact factor: 3.857

5.  Killing of human melanoma cells by the membrane attack complex of human complement as a function of its molecular composition.

Authors:  D E Martin; F J Chiu; I Gigli; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

6.  Bacterial killing by complement. C9-mediated killing in the absence of C5b-8.

Authors:  J R Dankert; A F Esser
Journal:  Biochem J       Date:  1987-06-01       Impact factor: 3.857

7.  Formation of transmural complement pores in serum-sensitive Escherichia coli.

Authors:  S Bhakdi; G Kuller; M Muhly; S Fromm; G Seibert; J Parrisius
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

8.  Mechanism of resistance to complement-mediated killing of bacteria encoded by the Salmonella typhimurium virulence plasmid gene rck.

Authors:  E J Heffernan; S Reed; J Hackett; J Fierer; C Roudier; D Guiney
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin.

Authors:  Jiusheng Deng; Daniel Gold; Philip T LoVerde; Zvi Fishelson
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules.

Authors:  E R Podack; J D Young; Z A Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.